1. Home
  2. GBIO vs DOUG Comparison

GBIO vs DOUG Comparison

Compare GBIO & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • DOUG
  • Stock Information
  • Founded
  • GBIO 2016
  • DOUG 1911
  • Country
  • GBIO United States
  • DOUG United States
  • Employees
  • GBIO N/A
  • DOUG N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • DOUG Building operators
  • Sector
  • GBIO Health Care
  • DOUG Real Estate
  • Exchange
  • GBIO Nasdaq
  • DOUG Nasdaq
  • Market Cap
  • GBIO 145.5M
  • DOUG 166.2M
  • IPO Year
  • GBIO 2020
  • DOUG N/A
  • Fundamental
  • Price
  • GBIO $2.50
  • DOUG $1.82
  • Analyst Decision
  • GBIO Buy
  • DOUG
  • Analyst Count
  • GBIO 4
  • DOUG 0
  • Target Price
  • GBIO $7.50
  • DOUG N/A
  • AVG Volume (30 Days)
  • GBIO 63.3K
  • DOUG 676.3K
  • Earning Date
  • GBIO 08-07-2024
  • DOUG 11-05-2024
  • Dividend Yield
  • GBIO N/A
  • DOUG N/A
  • EPS Growth
  • GBIO N/A
  • DOUG N/A
  • EPS
  • GBIO N/A
  • DOUG N/A
  • Revenue
  • GBIO $13,174,000.00
  • DOUG $951,674,000.00
  • Revenue This Year
  • GBIO $99.36
  • DOUG $3.85
  • Revenue Next Year
  • GBIO N/A
  • DOUG $17.40
  • P/E Ratio
  • GBIO N/A
  • DOUG N/A
  • Revenue Growth
  • GBIO 1397.05
  • DOUG N/A
  • 52 Week Low
  • GBIO $0.86
  • DOUG $1.00
  • 52 Week High
  • GBIO $4.65
  • DOUG $3.16
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 49.32
  • DOUG 54.58
  • Support Level
  • GBIO $2.13
  • DOUG $1.42
  • Resistance Level
  • GBIO $2.49
  • DOUG $1.91
  • Average True Range (ATR)
  • GBIO 0.21
  • DOUG 0.17
  • MACD
  • GBIO 0.01
  • DOUG -0.01
  • Stochastic Oscillator
  • GBIO 46.91
  • DOUG 61.01

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.

Share on Social Networks: